Analysts Anticipate Biodel Inc. (ALBO) to Post ($0.87) EPS
Shares of Biodel Inc. (NASDAQ:ALBO) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Analysts have set a 1-year consensus price target of $40.00 for the company and are expecting that the company will post ($0.87) earnings per share for the current quarter, according to Zacks. Zacks has also given Biodel an industry rank of 164 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research downgraded Biodel from a “hold” rating to a “sell” rating in a research note on Monday, April 10th.
A number of hedge funds have recently bought and sold shares of ALBO. Vanguard Group Inc. increased its stake in Biodel by 4.9% in the first quarter. Vanguard Group Inc. now owns 29,869 shares of the biopharmaceutical company’s stock worth $717,000 after buying an additional 1,404 shares during the last quarter. Renaissance Technologies LLC increased its stake in Biodel by 0.5% in the first quarter. Renaissance Technologies LLC now owns 149,632 shares of the biopharmaceutical company’s stock worth $3,591,000 after buying an additional 794 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in Biodel by 4.5% in the first quarter. Geode Capital Management LLC now owns 13,746 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 588 shares during the last quarter. Institutional investors own 12.18% of the company’s stock.
Biodel (ALBO) traded up 20.8017% during midday trading on Wednesday, reaching $18.7001. The company’s stock had a trading volume of 40,799 shares. The stock’s market cap is $117.66 million. The stock’s 50 day moving average is $20.05 and its 200 day moving average is $21.36. Biodel has a 12-month low of $7.84 and a 12-month high of $37.69.
Biodel (NASDAQ:ALBO) last posted its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.10) by $0.04. Analysts anticipate that Biodel will post ($4.29) earnings per share for the current year.
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.